510(k) Report

510(k) · Cleared

Recalled · Class II · 2012

Ultrawave II EX 1320

K070805510(k) TraditionalCleared Jul 11, 2007110-day reviewClass II21 CFR 878.4810Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Quanta System Spa · GEX Powered Laser Surgical Instrument

Cleared on Jul 11, 2007 after a 110-day review. The FDA summary names its predicate without a number. 150 later devices descend from it. It has been recalled once.

Decided
Jul 11, 2007
Review
110 days
Class
Class II
Product code
GEX
Recalls
1
Predicates
0

150 later devices descend from it, 4 citing it directly.

Descendants, by year cleared 2008: 2 descendants cleared2013: 2 descendants cleared2009: 1 descendant cleared2018: 10 descendants cleared2011: 1 descendant cleared2012: 1 descendant cleared2014: 3 descendants cleared2015: 6 descendants cleared2022: 22 descendants cleared2020: 13 descendants cleared2019: 7 descendants cleared2016: 3 descendants cleared2024: 17 descendants cleared2017: 7 descendants cleared2025: 22 descendants cleared2023: 10 descendants cleared2026: 15 descendants cleared2021: 8 descendants cleared20052010201520202025
  1. This deviceK070805 Ultrawave II EX 1320Quanta System Spa · 2007
  2. Descendant · cites it directly · 112 of its ownK081352 Profile Multi-Platform SystemSciton, Inc · 2008
  3. Descendant · 2 generations on · 111 of its ownK101916 Joule Multi-Platform SystemSciton, Inc · 2011
  4. Descendant · cites it directly · 96 of its ownK083207 Ultrawave Iii EX 1320Quanta System Spa · 2008 · Recalled
  5. Descendant · 3 generations on · 70 of its ownK132806 Fotona F-22 Laser Handpiece (F-Runner), Fotona FS-01 Laser HandpieceFotona D.D. · 2014
  6. Descendant · 4 generations on · 62 of its ownK143723 SP Dynamis, SP Spectro, XS Dynamis, XP Dynamis, XP SpectroFotona D.D. · 2015

Showing 5 of 150 descendants. See all descendants

Descendants cleared per year

2008: 22009: 12011: 12012: 12013: 22014: 32015: 62016: 32017: 72018: 102019: 72020: 132021: 82022: 222023: 102024: 172025: 222026: 15
2008high 22 (2022) · low 0 (2010)2026

Most influential descendants

Showing 5 of 150 · See all
  • K081352Profile Multi-Platform SystemSciton, Inc · 2008 · cites it directly112descendants
  • K101916Joule Multi-Platform SystemSciton, Inc · 2011 · 2 generations on111descendants
  • K083207Ultrawave Iii EX 1320Quanta System Spa · 2008 · cites it directly96descendants
  • K132806Fotona F-22 Laser Handpiece (F-Runner), Fotona FS-01 Laser HandpieceFotona D.D. · 2014 · 3 generations on70descendants
  • K143723SP Dynamis, SP Spectro, XS Dynamis, XP Dynamis, XP SpectroFotona D.D. · 2015 · 4 generations on62descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K070805Ultrawave II EX 1320Quanta System Spa2007—
+1K081352Profile Multi-Platform SystemSciton, Inc2008—
+2K101916Joule Multi-Platform SystemSciton, Inc2011—
+1K083207Ultrawave Iii EX 1320Quanta System Spa20081
+3K132806Fotona F-22 Laser Handpiece (F-Runner), Fotona FS-01 Laser HandpieceFotona D.D.2014—
+4K143723SP Dynamis, SP Spectro, XS Dynamis, XP Dynamis, XP SpectroFotona D.D.2015—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200820
200910
201110
201210
201320
201430
201560
201630
201770
2018100
201970
2020130
202180
2022220
2023100
2024170
2025220
2026150
FIG. 1 — Lineage of K070805, 2007–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GEX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GEX device

  1. #1 K222064 The Alma Soprano Titaniumscore 38.1 · 24 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (6)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—Adept Medical Concept's Adept 1064/755 Laser
Named without a submission number
—
*—Sciton, Inc.'s Profile 1320 Laser
Named without a submission number
—
*—Altus Medical Inc.'s Altus Medical Coolidge Laser Systems and Accessories
Named without a submission number
—
*—Quanta System's Eterna Giovinezza System
Named without a submission number
—
*—Cynosure's YAG Family of Lasers
Named without a submission number
—
*—Cynosure Apogee Elite laser
Named without a submission number
—

What descends from it? (150)

See all 150

4 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K081352Profile Multi-Platform SystemSciton, Inc2008112
K083207Ultrawave Iii EX 1320Quanta System Spa200896
K090571Alma Lasers ALEX755 ModuleAlma Lasers, Ltd.200958
K130256MDK Multi-Applications PlatformQuanta System Spa201338

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Nov 7, 2012Class IIZ-0693-2013Labeling False and MisleadingQuanta System S.p.A, Italy, is notifying U.S. consignees that their website contained promotional materials for products distributed in the U.S. which did not specify that some of the claims made therein were not meant to apply to the…

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K081352 (Sciton, Inc, 2008) has gone furthest, with 112 descendants of its own.

How does its category compare?

All GEX devices

GEX Powered Laser Surgical Instrument: FDA decisions, review times, recalls and adverse event reports over 20 years. 2007, this device’s year, is highlighted.

FDA decisions per year · GEX

83in 2025

2007: 732008: 1072009: 692010: 502011: 412012: 452013: 462014: 612015: 472016: 512017: 672018: 512019: 412020: 522021: 532022: 602023: 522024: 822025: 832026 (partial year): 57
2007high 107 (2008) · low 41 (2011)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GEX

90in 2025

2007: 79 days median2008: 86 days median2009: 100 days median2010: 96 days median2011: 83 days median2012: 118 days median2013: 144 days median2014: 147 days median2015: 112 days median2016: 114 days median2017: 90 days median2018: 78 days median2019: 88 days median2020: 90 days median2021: 123 days median2022: 152 days median2023: 87 days median2024: 90 days median2025: 90 days median2026 (partial year): 90 days median
2007high 152 (2022) · low 78 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GEX

3in 2024

2007: 92008: 22010: 42011: 182012: 52013: 32014: 62016: 12017: 5, 1 Class I2018: 52019: 62020: 12023: 62024: 32026 (partial year): 2
2007high 18 (2011) · low 0 (2009)2026

Class I (1 since 2007) Class II/III not classified

Adverse event reports per year · GEX

2,720in 2025

2007: 3422008: 2322009: 2092010: 1,7112011: 3,0242012: 2,0002013: 2,2362014: 2,0362015: 2,0992016: 2,5852017: 2,9772018: 3,5252019: 2,7092020: 2,1832021: 3,4652022: 2,2882023: 2,3372024: 2,1872025: 2,720
2007high 3,525 (2018) · low 209 (2009)2025

MAUDE reports naming product code GEX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200773799342
2008107862232
2009691000209
2010509641,711
20114183183,024
20124511852,000
20134614432,236
20146114762,036
20154711202,099
20165111412,585
201767905 (1)2,977
2018517853,525
2019418862,709
2020529012,183
20215312303,465
20226015202,288
2023528762,337
2024829032,187
2025839002,720
202657902—

What is it indicated for?

Nd:YAG 1064nm Intended for general surgical applications; dermatology/plastic surgery; endoscopic/laparoscopic surgery; general surgery; gynecology; ENT; hemostasis; neurosurgery; oculoplastics; pulmonary surgery; thoracic surgery; urology; and orthopedics. General Surgical Applications: Incision, excision, coagulation, hemostasis, vaporization, and/or ablation of soft tissue in dermatology/plastic surgery, endoscopic/laparoscopic general surgery…

Read the full statement (623 words)

Nd:YAG 1064nm

Intended for general surgical applications; dermatology/plastic surgery;

endoscopic/laparoscopic surgery; general surgery; gynecology; ENT; hemostasis;

neurosurgery; oculoplastics; pulmonary surgery; thoracic surgery; urology; and

orthopedics.

General Surgical Applications:

Incision, excision, coagulation, hemostasis, vaporization, and/or ablation of soft tissue in

dermatology/plastic surgery, endoscopic/laparoscopic general surgery, gastroenterology,

general surgery, gynecology, head and neck/-otorhinolaryngology (ENT), neurosurgery,

oculoplastics, orthopedics, pulmonary surgery, thoracic surgery and urology.

Dermatology/Plastic Surgery:

Coagulation and hemostasis of benign vascular lesions such as, but not limited to, port

wine stains, hemangiomas, warts, telangiectasia, rosacea, venus lake, leg and spider

veins and poikiloderma of Civatte and treatment of benign cutaneous lesions such as

warts, scars, striae and psoriasis. It addition, the laser is intended for the treatment of

benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos

(sun spots), cafe au lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin

tags, keratoses, tattoos (significant reduction in the intensity of blue and/or black

tattoos), and plaques.

The ULTRAWAVE II EX 1320 laser is also indicated for pigmented lesions to reduce

lesion size, for patients with lesions that would potentially benefit from aggressive

treatment, and for patients with lesions that have not responded to other laser

treatments.

The ULTRAWAVE H1 EX 1320 laser is also indicated for the treatment of facial wrinkles

and wrinkles such as, but not limited to, periocular and periorbital wrinkles.

The ULTRA4WAVE H EX 1320 is indicated for the removal of unwanted hair, for the

stable long-term, or permanent, hair reduction through selective targeting of melanin in

hair follicles, and for the treatment of pseudofolliculitis barbae (PFB).

The ULTRAWAVE II EX 1320 is indicated for the reduction of red pigmentation in

hypertrophic and keloid scars where vascularity is an integral part of the scar.

The ULTRAWAVE II EX 1320 is indicated for use on all skin types (Fitzpatrick I-VI)

including tanned skin, and the removal and permanent reduction of unwanted hair in

Fitzpatrick I-VI, including suntanned skin types.

Orthopedics:

Cutting, ablation, and/or hemostasis of intra-articular tissue in orthopedic surgical and

arthroscopic applications.

Pulmonary Surgery:

Palliative treatment of benign and malignant pulmonary airway obtructions, including

squamous cell carcinoma, adenocarcinoma, carcinoid, benign tumors, granulomas, and

benign strictures.

Thoracic Surgery:

Incision, excision, coagulating and vaporization of soft tissue. Thoracic applications,

including but not limited to, isolation of vessels for endarterectomy and/or by-pass

grafts, wedge resections, thoractomy, formation of pacemaker pockets; vaporization,

coagulation, incision/excision, debulking, and ablation of lung tissue (thoracoscopy).

Urology:

All applications including superficial urinary bladder tumors, invasive bladder

carcinoma, urethral strictures and lesions of the external genitalia (including condyloma

acuminate).

Nd:YAG 1320nm

Indicated for use in general surgery and dermatology for the incision, excision, ablation,

vaporization, coagulation and haemostasis of soft tissue. It is also indicated for the

treatment of periorbital and perioral wrinkles, fine lines and wrinkles, and the treatment

of back acne and atrophic acne scars.

Alexandrite 755nm

Intended for coagulation and hemostatis of vascular lesions and the removal and

permanent reduction of unwanted hair in Fitzpatrick skin types I-VI, including

suntanned skin types. Also indicated for pigmented lesions and wrinkles.

/PL

590-1200nm: 625-1200nm; 650-1200nm

Indicated for permanent hair reduction.

550-1200nm; 570-1200nm

Indicated for photocoagulation of dermatological vascular lesion ( i.e.,face telangiectasia),

photothermolysis of blood vessels (treatment of facial and leg veins), and treatment of

benign pigmented lesions.

400-1200nm

Indicated for inflammatory acne (acne vulgaris).

Integrated Skin Cooler

The intended use of the integrated cooling system in the ULTRAWAVE II EX 1320

hand piece is to provide cooling of the skin prior to laser treatment, for the reduction of pain

during laser treatment, to allow for the use of higher fluencies for laser treatments such

as hair removal and vascular lesion, and to reduce

the potential side effects of laser treatments.

Any other different use is considered incoimect.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K070805: Ultrawave II EX 1320.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K070805

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026